Sign inJoin free

Watch / Small Cap

LTR Pharma sniffs out new solution for digestive disorders

8 May 20256:08

LTR Pharma sniffs out new solution for digestive disorders

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

LTR Pharma (ASX: LTP), a clinical stage biopharmaceutical company, collaborates with Strategic Drug Solutions to develop a nasal spray targeting esophageal motility disorders. Lee Rodne from LTR emphasises the high prevalence of these disorders, affecting 20% of individuals over 50, highlighting the need for non-invasive treatments.

Lee highlights the $4.5 billion global market for OMD treatments, with the US being a major focus. Their nasal spray technology aims to offer a more efficient and convenient alternative compared to current invasive procedures. The company aims to bring this innovative product to the Australian market soon, alongside expanding into Europe, Asia, and South America.

LTR Pharma (ASX: LTP) also continues its success with other nasal spray products, like Spontan, for erectile dysfunction. With a strong cash position of $34 million, the company is poised for further market launches, including the US market in 2026, showcasing their commitment to revolutionising drug delivery.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy